{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:21:51Z","timestamp":1787628111605,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020193","name":"Novartis Pharmaceuticals Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020193","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001775","name":"University of Technology Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001775","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40273-022-01188-w","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T01:02:50Z","timestamp":1666314170000},"page":"175-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0979-1366","authenticated-orcid":false,"given":"Amy","family":"Gye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Goodall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"De Abreu Lourenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"1188_CR1","first-page":"2428","volume":"8","author":"H Lloyd-Williams","year":"2020","unstructured":"Lloyd-Williams H, Hughes DA. A systematic review of economic evaluations of advanced therapy medicinal products. Br J Clin Pharmacol. 2020;8:2428\u201343.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1188_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.19.01558","volume":"38","author":"MD Whittington","year":"2020","unstructured":"Whittington MD, McQueen RB, Campbell JD. Valuing chimeric antigen receptor T-cell therapy: current evidence, uncertainties, and payment implications. J Clin Oncol. 2020;38(4):359\u201366.","journal-title":"J Clin Oncol"},{"key":"1188_CR3","unstructured":"National Institute for Health and Care Excellence (NICE). Final appraisal document\u2014Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. NICE; 2018. https:\/\/www.nice.org.uk\/guidance\/ta567\/documents\/final-appraisal-determination-document. Accessed 21 Dec 2020."},{"key":"1188_CR4","unstructured":"National Institute for Health and Care Excellence. Final appraisal document\u2014Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. NICE; 2018. https:\/\/www.nice.org.uk\/guidance\/ta554\/documents\/final-appraisal-determination-document. Accessed 21 Dec 2020."},{"issue":"12","key":"1188_CR5","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s40273-020-00956-w","volume":"38","author":"A Angelis","year":"2020","unstructured":"Angelis A, Naci H, Hackshaw A. Recalibrating health technology assessment methods for cell and gene therapies. Pharmacoeconomics. 2020;38(12):1297\u2013308. https:\/\/doi.org\/10.1007\/s40273-020-00956-w.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1188_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jval.2021.07.008","volume":"25","author":"AGS Gye","year":"2021","unstructured":"Gye AGS, De Abreu LR. A systematic review of health technology assessments of chimeric antigen receptor T-cell therapies in young compared with older patients. Value Health. 2021;25(1):47\u201358. https:\/\/doi.org\/10.1016\/j.jval.2021.07.008.","journal-title":"Value Health."},{"issue":"9","key":"1188_CR7","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10198-020-01212-w","volume":"21","author":"D Coyle","year":"2020","unstructured":"Coyle D, Durand-Zaleski I, Farrington J, et al. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. Eur J Health Econ. 2020;21(9):1421\u201337. https:\/\/doi.org\/10.1007\/s10198-020-01212-w.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"1188_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2019.12.008","volume":"23","author":"M Dabbous","year":"2020","unstructured":"Dabbous M, Chachoua L, Caban A, Toumi M. Managed entry agreements: policy analysis from the European perspective. Value Health. 2020;23(4):425\u201333. https:\/\/doi.org\/10.1016\/j.jval.2019.12.008.","journal-title":"Value Health."},{"issue":"6","key":"1188_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jval.2019.03.012","volume":"22","author":"MF Drummond","year":"2019","unstructured":"Drummond MF, Neumann PJ, Sullivan SD, et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value Health. 2019;22(6):661\u20138.","journal-title":"Value Health"},{"issue":"3","key":"1188_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10198-018-1007-x","volume":"20","author":"B Jonsson","year":"2019","unstructured":"Jonsson B, Hampson G, Michaels J, Towse A, von der Schulenburg JMG, Wong O. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. Eur J Health Econ. 2019;20(3):427\u201338.","journal-title":"Eur J Health Econ"},{"issue":"3","key":"1188_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.healthpol.2010.02.005","volume":"96","author":"JJ Carlson","year":"2010","unstructured":"Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96(3):179\u201390. https:\/\/doi.org\/10.1016\/j.healthpol.2010.02.005.","journal-title":"Health Policy"},{"issue":"19","key":"1188_CR12","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/jama.2017.15218","volume":"318","author":"PB Bach","year":"2017","unstructured":"Bach PB, Giralt SA, Saltz LB. FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug. JAMA. 2017;318(19):1861\u20132. https:\/\/doi.org\/10.1001\/jama.2017.15218.","journal-title":"JAMA"},{"issue":"6","key":"1188_CR13","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jval.2018.12.004","volume":"22","author":"JF Barlow","year":"2019","unstructured":"Barlow JF, Yang M, Teagarden JR. Are payers ready, willing, and able to provide access to new durable gene therapies? Value Health. 2019;22(6):642\u20137. https:\/\/doi.org\/10.1016\/j.jval.2018.12.004.","journal-title":"Value Health"},{"issue":"5","key":"1188_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","volume":"16","author":"LP Garrison Jr","year":"2013","unstructured":"Garrison LP Jr, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16(5):703\u201319. https:\/\/doi.org\/10.1016\/j.jval.2013.04.011.","journal-title":"Value Health"},{"key":"1188_CR15","unstructured":"Crabb N, Stevens, A for the Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE). Exploring the assessment and appraisal of regenerative medicines and cell therapy products. 2016:19. https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/Science%20policy%20and%20research\/Regenerative-medicine-study-march-2016.pdf. Accessed 21 Dec 2020."},{"issue":"1","key":"1188_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jval.2017.07.009","volume":"21","author":"JD Brown","year":"2018","unstructured":"Brown JD, Sheer R, Pasquale M, et al. Payer and pharmaceutical manufacturer considerations for outcomes-based agreements in the United States. Value Health. 2018;21(1):33\u201340. https:\/\/doi.org\/10.1016\/j.jval.2017.07.009.","journal-title":"Value Health"},{"issue":"1","key":"1188_CR17","doi-asserted-by":"publisher","first-page":"1573164","DOI":"10.1080\/20016689.2019.1573164","volume":"7","author":"J J\u00f8rgensen","year":"2019","unstructured":"J\u00f8rgensen J, Mungapen L, Kefalas P. Data collection infrastructure for patient outcomes in the UK\u2014opportunities and challenges for cell and gene therapies launching. J Mark Access Health Policy. 2019;7(1):1573164. https:\/\/doi.org\/10.1080\/20016689.2019.1573164.","journal-title":"J Mark Access Health Policy"},{"issue":"1","key":"1188_CR18","doi-asserted-by":"publisher","first-page":"1715536","DOI":"10.1080\/20016689.2020.1715536","volume":"8","author":"J J\u00f8rgensen","year":"2020","unstructured":"J\u00f8rgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. J Mark Access Health Policy. 2020;8(1):1715536. https:\/\/doi.org\/10.1080\/20016689.2020.1715536.","journal-title":"J Mark Access Health Policy."},{"issue":"4","key":"1188_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2217\/rme-2020-0169","volume":"16","author":"J J\u00f8rgensen","year":"2021","unstructured":"J\u00f8rgensen J, Kefalas P. The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regen Med. 2021;16(4):405\u201322. https:\/\/doi.org\/10.2217\/rme-2020-0169.","journal-title":"Regen Med"},{"key":"1188_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.594446","volume":"11","author":"S Michelsen","year":"2020","unstructured":"Michelsen S, Nachi S, Van Dyck W, Simoens S, Huys I. Barriers and opportunities for implementation of outcome-based spread payments for high-cost, one-shot curative therapies. Front Pharmacol. 2020;11: 594446. https:\/\/doi.org\/10.3389\/fphar.2020.594446.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1188_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.healthpol.2014.05.005","volume":"117","author":"A Vitry","year":"2014","unstructured":"Vitry A, Roughead E. Managed entry agreements for pharmaceuticals in Australia. Health Policy. 2014;117(3):345\u201352. https:\/\/doi.org\/10.1016\/j.healthpol.2014.05.005.","journal-title":"Health Policy"},{"issue":"12","key":"1188_CR22","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40261-020-00972-w","volume":"40","author":"AE Kim","year":"2020","unstructured":"Kim AE, Choi DH, Chang J, Kim SH. Performance-based risk-sharing arrangements (PBRSA): is it a solution to increase bang for the buck for pharmaceutical reimbursement strategy for our nation and around the world? Clin Drug Investig. 2020;40(12):1107\u201313. https:\/\/doi.org\/10.1007\/s40261-020-00972-w.","journal-title":"Clin Drug Investig"},{"issue":"9757","key":"1188_CR23","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","volume":"376","author":"C Parker","year":"2010","unstructured":"Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376(9757):2009\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(10)62002-8.","journal-title":"Lancet"},{"issue":"5","key":"1188_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"1188_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002287","author":"JE Levine","year":"2021","unstructured":"Levine JE, Grupp SA, Pulsipher MA, et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-002287.","journal-title":"J Immunother Cancer"},{"key":"1188_CR26","unstructured":"Novartis Pharmaceuticals Australia. Australian Product Information\u2014Kymriah (tisagenlecleucel) suspension. Therapeutic Goods Administration (TGA); 2021. 14 September 2021. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2021-PI-02122-1&d=20220223172310101. Accessed 23 Feb 2022."},{"key":"1188_CR27","unstructured":"Medical Services Advisory Commitee (MSAC). Public summary document: application no. 1519\u2014Tisagenlecleucel for treatment of refractory CD19-positive leukaemia and lymphoma. April 2019. MSAC; 2019. http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/BE2E1EB50ED57442CA2581F4000C1723\/$File\/1519-Final%20PSD-April%202019_redacted.pdf. Accessed 21 Dec 2020."},{"key":"1188_CR28","unstructured":"Amgen Australia. Australian Product Information\u2014Blincyto (blinatumomab) powder for injection. Therapeutic Goods Administration (TGA); 2021. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2015-PI-02791-1. Accessed 23 Feb 2022."},{"issue":"36","key":"1188_CR29","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A Von Stackelberg","year":"2016","unstructured":"Von Stackelberg A, Locatelli F, Zugmaier G. Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(36):4381\u20139.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1188_CR30","unstructured":"Therapeutic Goods Administration (TGA). Australian Product Information\u2014Besponsa (inotuzumab ozogamicin). 2021. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2018-PI-01685-1&d=20220815172310101. Accessed 15 Aug 2022."},{"key":"1188_CR31","unstructured":"Institute for Clincial and Economic Review (ICER). Adapted value assessment methods for high-impact \"single and short-term therapies\" (SSTs). ICER; 2019:1-13. http:\/\/icer.org\/wp-content\/uploads\/2019\/11\/ICER_SST_FinalAdaptations_111219-1.pdf. Accessed 21 Dec 2020."},{"issue":"12","key":"1188_CR32","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","volume":"172","author":"MD Whittington","year":"2018","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr. 2018;172(12):1161\u20138.","journal-title":"JAMA Pediatr"},{"issue":"2","key":"1188_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0035","volume":"2","author":"MD Whittington","year":"2019","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma. JAMA Netw Open. 2019;2(2): e190035.","journal-title":"JAMA Netw Open"},{"issue":"16","key":"1188_CR34","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"key":"1188_CR35","unstructured":"Woods B, Sideris E, Palmer S, Latimer N, Soares, M. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care; a critical review. 2017. http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2017\/06\/Partitioned-Survival-Analysis-final-report.pdf. Accessed 27 Jan 2021."},{"key":"1188_CR36","unstructured":"Medical Services Advisory Commitee (MSAC). Guidelines for preparing assessments for the Medical Services Advisory Committee. 2021; version 1.0. May 2021. http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/E0D4E4EDDE91EAC8CA2586E0007AFC75\/$File\/MSAC%20Guidelines-complete-16-FINAL(18May21).pdf. Accessed 7 Sept 2021."},{"key":"1188_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"1188_CR38","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1536867X1801700402","volume":"17","author":"Y Wei","year":"2017","unstructured":"Wei Y, Royston P. Reconstructing time-to-event data from published Kaplan\u2013Meier curves. Stata J. 2017;17(4):786\u2013802.","journal-title":"Stata J"},{"key":"1188_CR39","unstructured":"RStudio: Integrated Development Environment for R. 2015. http:\/\/www.rstudio.com\/"},{"key":"1188_CR40","unstructured":"Stata Statistical Software: Release 13. StataCorp LP; 2013."},{"key":"1188_CR41","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies. 2017. https:\/\/www.cadth.ca\/guidelines-economic-evaluation-health-technologies-canada-4th-edition. Accessed 4 Nov 2021."},{"key":"1188_CR42","unstructured":"Latimer N. NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data. 2011. http:\/\/www.nicedsu.org.uk. Accessed 8 Sept 2021."},{"key":"1188_CR43","unstructured":"Australian Government Department of Health. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee (Version 5.0). 2016. https:\/\/pbac.pbs.gov.au\/content\/information\/files\/pbac-guidelines-version-5.pdf. Accessed 10 Nov 2021."},{"key":"1188_CR44","unstructured":"Australian Bureau of Statistics (ABS). Data from: Life Tables, 2018\u20132020. 2021."},{"issue":"4","key":"1188_CR45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/pbc.20922","volume":"48","author":"AC MacArthur","year":"2007","unstructured":"MacArthur AC, Spinelli JJ, Rogers PC, Goddard KJ, Abanto ZU, McBride ML. Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada. Pediatr Blood Cancer. 2007;48(4):460\u20137. https:\/\/doi.org\/10.1002\/pbc.20922.","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"1188_CR46","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108. https:\/\/doi.org\/10.1097\/00005650-199711000-00002.","journal-title":"Med Care"},{"issue":"3","key":"1188_CR47","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/ejh.13007","volume":"100","author":"LF Casado","year":"2018","unstructured":"Casado LF, Hernandez JA, Jarque I, Echave M, Casado MA, Castro A. Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia. Eur J Haematol. 2018;100(3):264\u201372. https:\/\/doi.org\/10.1111\/ejh.13007.","journal-title":"Eur J Haematol"},{"issue":"3","key":"1188_CR48","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cncr.11098","volume":"97","author":"L Sung","year":"2003","unstructured":"Sung L, Buckstein R, Doyle JJ, Crump M, Detsky AS. Treatment options for patients with acute myeloid leukemia with a matched sibling donor. Cancer. 2003;97(3):592\u2013600.","journal-title":"Cancer"},{"key":"1188_CR49","unstructured":"Reserve Bank of Australia (RBA). Inflation calculator. https:\/\/www.rba.gov.au\/calculator\/. Accessed 4 Apr 2022."},{"key":"1188_CR50","unstructured":"Reserve Bank of Australia (RBA). Exchange rates. https:\/\/www.rba.gov.au\/statistics\/frequency\/exchange-rates.html. Accessed 4 Apr 2022."},{"key":"1188_CR51","unstructured":"Australian Government Department of Health. Pharmaceutical Benefits Scheme (PBS). www.pbs.gov.au. Accessed 22 Feb 2022."},{"key":"1188_CR52","unstructured":"Gordon R, Thompson C, Carolan J, Eckstein G, Rostron C. A costing study of blood and marrow transplantation services in NSW: final report. 2009."},{"issue":"3","key":"1188_CR53","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.clinthera.2016.01.004","volume":"38","author":"N Muszbek","year":"2016","unstructured":"Muszbek N, Kadambi A, Lanitis T, et al. The cost-effectiveness of pixantrone for third\/fourth-line treatment of aggressive non-Hodgkin\u2019s lymphoma. Clin Ther. 2016;38(3):503\u201315. https:\/\/doi.org\/10.1016\/j.clinthera.2016.01.004.","journal-title":"Clin Ther"},{"issue":"32","key":"1188_CR54","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","volume":"36","author":"JK Lin","year":"2018","unstructured":"Lin JK, Lerman BJ, Barnes JI, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol. 2018;36(32):3192\u2013202.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1188_CR55","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/djy193","volume":"111","author":"RR Sarkar","year":"2019","unstructured":"Sarkar RR, Gloude NJ, Schiff D, Murphy JD. Cost-effectiveness of chimeric antigen receptor t-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia. J Natl Cancer Inst. 2019;111(7):719\u201326.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1188_CR56","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2019.5909","volume":"6","author":"J Furzer","year":"2020","unstructured":"Furzer J, Gupta S, Nathan PC, et al. Cost-effectiveness of tisagenlecleucel vs standard care in high-risk relapsed pediatric acute lymphoblastic leukemia in Canada. JAMA Oncol. 2020;6(3):393\u2013401.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1188_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21070","volume":"21","author":"R Hettle","year":"2017","unstructured":"Hettle R, Corbett M, Hinde S, et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017;21(7):1\u2013204.","journal-title":"Health Technol Assess"},{"issue":"24","key":"1188_CR58","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.18.02079","volume":"37","author":"JK Lin","year":"2019","unstructured":"Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol. 2019;37(24):2105\u201319.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1188_CR59","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s40273-017-0535-z","volume":"35","author":"JJ Carlson","year":"2017","unstructured":"Carlson JJ, Chen S, Garrison LP Jr. Performance-based risk-sharing arrangements: an updated international review. Pharmacoeconomics. 2017;35(10):1063\u201372. https:\/\/doi.org\/10.1007\/s40273-017-0535-z.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1188_CR60","doi-asserted-by":"publisher","first-page":"1635842","DOI":"10.1080\/20016689.2019.1635842","volume":"7","author":"J J\u00f8rgensen","year":"2019","unstructured":"J\u00f8rgensen J, Kefalas P. Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate. J Mark Access Health Policy. 2019;7(1):1635842. https:\/\/doi.org\/10.1080\/20016689.2019.1635842.","journal-title":"J Mark Access Health Policy."},{"issue":"9","key":"1188_CR61","first-page":"632","volume":"21","author":"LP Garrison Jr","year":"2015","unstructured":"Garrison LP Jr, Carlson JJ, Bajaj PS, et al. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. Am J Manag Care. 2015;21(9):632\u201340.","journal-title":"Am J Manag Care"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01188-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01188-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01188-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T20:00:48Z","timestamp":1674849648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01188-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01188-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"4 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The complete section of ESM has been included in the original version of the article.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The data utilized in this study were sourced from clinical trials that were conducted according to the ethical principles of the Declaration of Helsinki. This research was considered appropriate to be conducted under the UTS Human Research Ethics Committee (UTS HREC REF NO. ETH18-2507).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Amy Gye is an employee of Novartis Pharmaceuticals Australia. This research is part of an Industry Doctorate Program at the Centre for Health Economics Research and Evaluation, University of Technology Sydney in collaboration with Novartis Pharmaceuticals Australia. Novartis Pharmaceuticals Australia provides a Research Support Fee. Ms. Gye receives a salary from Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Source of funding"}},{"value":"Amy Gye is an employee of Novartis Pharmaceuticals Australia. No other disclosures were reported.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Concept and design: Gye, Goodall, De Abreu Lourenco; acquisition of data: Gye; analysis and interpretation of data: Gye; drafting of the manuscript: Gye, Goodall, De Abreu Lourenco; critical revision of the paper for important intellectual content: Goodall, De Abreu Lourenco; supervision: Goodall, De Abreu Lourenco.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Analysis of clinical trial data was conducted retrospectively, and ethics approval was granted by the University of Technology Sydney Human Research Ethics Committee.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}